Dexcom rtCGM is Likely to be Cost-Saving, Study Suggests

Author's Avatar
May 03, 2023

DexCom%2C+Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced today the publication of a study “Cost-Effectiveness of a Real-Time Continuous Glucose Monitoring System Versus Self-Monitoring of Blood Glucose in People with Type 2 Diabetes on Insulin Therapy in the UK” in Diabetes Therapy 1.